254 related articles for article (PubMed ID: 34079038)
1. BAFF predicts immunogenicity in older patients with rheumatoid arthritis treated with TNF inhibitors.
Hernández-Breijo B; Navarro-Compán V; Plasencia-Rodríguez C; Parodis I; Gehin JE; Martínez-Feito A; Novella-Navarro M; Mezcua A; Warren DJ; Nozal P; Pascual-Salcedo D; Balsa A
Sci Rep; 2021 Jun; 11(1):11632. PubMed ID: 34079038
[TBL] [Abstract][Full Text] [Related]
2. Presence of anti-nuclear antibodies is a risk factor for the appearance of anti-drug antibodies during infliximab or adalimumab therapy in patients with rheumatoid arthritis.
Mori A; Saito T; Takahashi M; Shibata M; Tsuji G; Hatachi S; Takahashi S; Kumagai S
PLoS One; 2020; 15(12):e0243729. PubMed ID: 33315881
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic drug monitoring of adalimumab in RA: no predictive value of adalimumab serum levels and anti-adalimumab antibodies for prediction of response to the next bDMARD.
Ulijn E; den Broeder N; Wientjes M; van Herwaarden N; Meek I; Tweehuysen L; van der Maas A; van den Bemt BJ; den Broeder AA
Ann Rheum Dis; 2020 Jul; 79(7):867-873. PubMed ID: 32317314
[TBL] [Abstract][Full Text] [Related]
4. Optimizing biological treatment in rheumatoid arthritis with the aid of therapeutic drug monitoring.
Eng GP
Dan Med J; 2016 Nov; 63(11):. PubMed ID: 27808043
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the clinical effectiveness of tumour necrosis factor inhibitors and abatacept after insufficient response to tocilizumab in patients with rheumatoid arthritis.
Akiyama M; Kaneko Y; Kondo H; Takeuchi T
Clin Rheumatol; 2016 Nov; 35(11):2829-2834. PubMed ID: 26971256
[TBL] [Abstract][Full Text] [Related]
6. Remission and low disease activity matrix tools: results in real-world rheumatoid arthritis patients under anti-TNF therapy.
Ganhão S; Lucas R; Fonseca JE; Santos MJ; Gonçalves DR; Madeira N; Silva C; Dourado E; Freitas R; Rodrigues J; Azevedo S; Rocha TM; Ferreira RM; Garcia S; Fernandes BM; Prata AR; Couto M; Torres RP; Cunha I; Costa L; Bernardes M
Acta Reumatol Port; 2020; 45(4):245-252. PubMed ID: 33420771
[TBL] [Abstract][Full Text] [Related]
7. Incidence and risk factors for adalimumab and infliximab anti-drug antibodies in rheumatoid arthritis: A European retrospective multicohort analysis.
Quistrebert J; Hässler S; Bachelet D; Mbogning C; Musters A; Tak PP; Wijbrandts CA; Herenius M; Bergstra SA; Akdemir G; Johannesson M; Combe B; Fautrel B; Chollet-Martin S; Gleizes A; Donnellan N; Deisenhammer F; Davidson J; Hincelin-Mery A; Dönnes P; Fogdell-Hahn A; De Vries N; Huizinga T; Abugessaisa I; Saevarsdottir S; Hacein-Bey-Abina S; Pallardy M; Broët P; Mariette X;
Semin Arthritis Rheum; 2019 Jun; 48(6):967-975. PubMed ID: 30420245
[TBL] [Abstract][Full Text] [Related]
8. Low Percentage of Signal Regulatory Protein α/β
Magill L; Adriani M; Berthou V; Chen K; Gleizes A; Hacein-Bey-Abina S; Hincelin-Mery A; Mariette X; Pallardy M; Spindeldreher S; Szely N; Isenberg DA; Manson JJ; Jury EC; Mauri C
Front Immunol; 2018; 9():2865. PubMed ID: 30568660
[TBL] [Abstract][Full Text] [Related]
9. Switching from an anti-TNF monoclonal antibody to soluble TNF-receptor yields better results than vice versa: An observational retrospective study of 72 rheumatoid arthritis switchers.
Lequerré T; Farran É; Ménard JF; Kozyreff-Meurice M; Vandhuick T; Tharasse C; Pouplin S; Daragon A; Le Loët X; Varin R; Vittecoq O
Joint Bone Spine; 2015 Oct; 82(5):330-7. PubMed ID: 25864942
[TBL] [Abstract][Full Text] [Related]
10. Drug immunogenicity in patients with inflammatory arthritis and secondary failure to tumour necrosis factor inhibitor therapies: the REASON study.
Balsa A; Sanmarti R; Rosas J; Martin V; Cabez A; Gómez S; Montoro M
Rheumatology (Oxford); 2018 Apr; 57(4):688-693. PubMed ID: 29365183
[TBL] [Abstract][Full Text] [Related]
11. Long-term exposure to monoclonal anti-TNF is associated with an increased risk of lymphoma in BAFF-transgenic mice.
Nocturne G; Ly B; Paoletti A; Pascaud J; Seror R; Nicco C; Mackay F; Vincent FB; Lazure T; Ferlicot S; Stimmer L; Pascal Q; Roulland S; Krzysiek R; Hacein-Bey S; Batteux F; Mariette X
Clin Exp Immunol; 2021 Aug; 205(2):169-181. PubMed ID: 33864242
[TBL] [Abstract][Full Text] [Related]
12. One-year risk of serious infection in patients treated with certolizumab pegol as compared with other TNF inhibitors in a real-world setting: data from a national U.S. rheumatoid arthritis registry.
Harrold LR; Litman HJ; Saunders KC; Dandreo KJ; Gershenson B; Greenberg JD; Low R; Stark J; Suruki R; Jaganathan S; Kremer JM; Yassine M
Arthritis Res Ther; 2018 Jan; 20(1):2. PubMed ID: 29329557
[TBL] [Abstract][Full Text] [Related]
13. Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis Changing Biologics in the USA.
Chastek B; Chen CI; Proudfoot C; Shinde S; Kuznik A; Wei W
Adv Ther; 2017 Nov; 34(11):2422-2435. PubMed ID: 29039054
[TBL] [Abstract][Full Text] [Related]
14. Calprotectin and TNF trough serum levels identify power Doppler ultrasound synovitis in rheumatoid arthritis and psoriatic arthritis patients in remission or with low disease activity.
Inciarte-Mundo J; Ramirez J; Hernández MV; Ruiz-Esquide V; Cuervo A; Cabrera-Villalba SR; Pascal M; Yagüe J; Cañete JD; Sanmarti R
Arthritis Res Ther; 2016 Jul; 18(1):160. PubMed ID: 27391315
[TBL] [Abstract][Full Text] [Related]
15. What Is the Clinical Relevance of TNF Inhibitor Immunogenicity in the Management of Patients With Rheumatoid Arthritis?
Mehta P; Manson JJ
Front Immunol; 2020; 11():589. PubMed ID: 32318070
[TBL] [Abstract][Full Text] [Related]
16. The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study.
Moots RJ; Xavier RM; Mok CC; Rahman MU; Tsai WC; Al-Maini MH; Pavelka K; Mahgoub E; Kotak S; Korth-Bradley J; Pedersen R; Mele L; Shen Q; Vlahos B
PLoS One; 2017; 12(4):e0175207. PubMed ID: 28448562
[TBL] [Abstract][Full Text] [Related]
17. Cost-utility analysis of certolizumab pegol in combination with methotrexate in patients with moderate-to-severe active rheumatoid arthritis in Greece.
Tzanetakos C; Tzioufas A; Goules A; Kourlaba G; Theodoratou T; Christou P; Maniadakis N
Rheumatol Int; 2017 Sep; 37(9):1441-1452. PubMed ID: 28523420
[TBL] [Abstract][Full Text] [Related]
18. Personalized medicine in rheumatoid arthritis: How immunogenicity impacts use of TNF inhibitors.
Bodio C; Grossi C; Pregnolato F; Favalli EG; Biggioggero M; Marchesoni A; Murgo A; Filippini M; Migliorini P; Caporali R; Pellerito R; Ciccia F; Sarzi-Puttini P; Perosa F; Paolazzi G; Hollan I; Bendtzen K; Meroni PL; Borghi MO
Autoimmun Rev; 2020 May; 19(5):102509. PubMed ID: 32173513
[TBL] [Abstract][Full Text] [Related]
19. Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real-life data from the LORHEN registry.
Favalli EG; Sinigaglia L; Becciolini A; Grosso V; Gorla R; Bazzani C; Atzeni F; Sarzi Puttini PC; Fusaro E; Pellerito R; Caporali R
Int J Rheum Dis; 2018 Feb; 21(2):422-430. PubMed ID: 29082659
[TBL] [Abstract][Full Text] [Related]
20. High frequency of antidrug antibodies and association of random drug levels with efficacy in certolizumab pegol-treated patients with rheumatoid arthritis: results from the BRAGGSS cohort.
Jani M; Isaacs JD; Morgan AW; Wilson AG; Plant D; Hyrich KL; Chinoy H; Barton A;
Ann Rheum Dis; 2017 Jan; 76(1):208-213. PubMed ID: 27245864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
